Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 867017 10.3389/fphar.2022.867017 Pharmacology Correction Corrigendum: Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study Carballo et al. Corrigendum: Non-Persistence TNFis on Healthcare Costs Carballo Nuria 1 2 * Garcia-Alzórriz Enric 3 Ferrández Olivia 1 2 Navarrete-Rouco María Eugenia 1 Durán-Jordà Xavier 4 Pérez-García Carolina 5 Monfort Jordi 2 5 Cots Francesc 3 Grau Santiago 1 2 1 Pharmacy Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain 2 Universitat Autònoma de Barcelona, Barcelona, Spain 3 Management Control Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain 4 Methodology and Biostatistics Support Unit, Institute Hospital del Mar for Medical Research (IMIM), Barcelona, Spain 5 Department of Rheumatology, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Nuria Carballo, ncarballo@psmar.cat

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

 07 03 2022 2022 13 867017 31 01 2022 31 01 2022 Copyright © 2022 Carballo, Garcia-Alzórriz, Ferrández, Navarrete-Rouco, Durán-Jordà, Pérez-García, Monfort, Cots and Grau. 2022 Carballo, Garcia-Alzórriz, Ferrández, Navarrete-Rouco, Durán-Jordà, Pérez-García, Monfort, Cots and Grau

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum onImpact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Studyby Carballo, N., Garcia-Alzórriz, E., Ferrández, O., Navarrete-Rouco, M. E., Durán-Jordà, X., Pérez-García, C., Monfort, J., Cots, F., and Grau, S. (2021). Front. Pharmacol. 12:752879. doi: 10.3389/fphar.2021.752879 rheumatic disease biologics persistence healthcare resource utilization and costs anti TNF agents

In the published article, there was an error regarding the affiliations for Nuria Carballo, Olivia Ferrández, Jordi Monfort and Santiago Grau. These authors all have an additional affiliation, listed as “Universitat Autònoma de Barcelona, Barcelona, Spain”.

In addition, there was an error in the Acknowledgements section in the original article. The following statement was should have been included:

“This study is part of a PhD programme in Medicine of the Universitat Autònoma de Barcelona. This study was presented, in part, as a poster at the EULAR Virtual Congress, 2–5 June 2021 in Paris, France.”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.